TD Asset Management Inc. reduced its position in shares of Radius Health Inc (NASDAQ:RDUS) by 7.3% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 47,041 shares of the biopharmaceutical company’s stock after selling 3,700 shares during the quarter. TD Asset Management Inc. owned approximately 0.10% of Radius Health worth $938,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other large investors have also recently bought and sold shares of the stock. State Board of Administration of Florida Retirement System lifted its stake in Radius Health by 2.9% during the 4th quarter. State Board of Administration of Florida Retirement System now owns 23,460 shares of the biopharmaceutical company’s stock valued at $387,000 after acquiring an additional 656 shares during the period. Rhumbline Advisers lifted its stake in shares of Radius Health by 1.4% in the 1st quarter. Rhumbline Advisers now owns 62,828 shares of the biopharmaceutical company’s stock worth $1,253,000 after purchasing an additional 889 shares during the period. Bank of Montreal Can lifted its stake in shares of Radius Health by 231.3% in the 4th quarter. Bank of Montreal Can now owns 1,544 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 1,078 shares during the period. Legal & General Group Plc lifted its stake in shares of Radius Health by 9.4% in the 4th quarter. Legal & General Group Plc now owns 17,227 shares of the biopharmaceutical company’s stock worth $284,000 after purchasing an additional 1,478 shares during the period. Finally, SG Americas Securities LLC bought a new position in shares of Radius Health in the 1st quarter worth approximately $157,000.
In other news, VP Joseph Francis Kelly acquired 2,000 shares of the company’s stock in a transaction on Friday, May 10th. The stock was bought at an average cost of $21.43 per share, with a total value of $42,860.00. Following the completion of the purchase, the vice president now directly owns 5,000 shares of the company’s stock, valued at $107,150. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Debasish Roychowdhury sold 4,800 shares of Radius Health stock in a transaction on Thursday, April 11th. The stock was sold at an average price of $22.15, for a total transaction of $106,320.00. Following the transaction, the director now directly owns 5,500 shares of the company’s stock, valued at $121,825. The disclosure for this sale can be found here. 4.00% of the stock is owned by insiders.
RDUS traded up $0.59 during trading on Friday, reaching $24.36. 1,314,257 shares of the company traded hands, compared to its average volume of 469,847. The business’s fifty day simple moving average is $21.96. Radius Health Inc has a 12-month low of $12.81 and a 12-month high of $30.54. The company has a current ratio of 5.16, a quick ratio of 5.04 and a debt-to-equity ratio of 6.75. The stock has a market capitalization of $1.10 billion, a P/E ratio of -4.99 and a beta of 0.99.
Radius Health (NASDAQ:RDUS) last posted its earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.94) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.95) by $0.01. Radius Health had a negative net margin of 176.84% and a negative return on equity of 233.12%. The firm had revenue of $29.84 million during the quarter, compared to analyst estimates of $35.35 million. During the same period last year, the firm posted ($1.11) earnings per share. Radius Health’s revenue for the quarter was up 105.1% compared to the same quarter last year. On average, equities research analysts predict that Radius Health Inc will post -3.59 earnings per share for the current year.
About Radius Health
Radius Health, Inc, a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide transdermal patch, a short-wear-time patch formulation of abaloparatide to treat postmenopausal women with osteoporosis; RAD1901, a selective estrogen receptor down-regulator for the treatment of metastatic breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator to treat breast cancer.
Featured Story: Should you buy a closed-end mutual fund?
Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.